Article
Oncology
Andrew G. Nicholson, Ming S. Tsao, Mary Beth Beasley, Alain C. Borczuk, Elisabeth Brambilla, Wendy A. Cooper, Sanja Dacic, Deepali Jain, Keith M. Kerr, Sylvie Lantuejoul, Masayuki Noguchi, Mauro Papotti, Natasha Rekhtman, Giorgio Scagliotti, Paul van Schil, Lynette Sholl, Yasushi Yatabe, Akihiko Yoshida, William D. Travis
Summary: The 2021 WHO Classification of Thoracic Tumours focuses on the application of genetics and molecular pathology, providing specific classifications and diagnostic criteria for various tumors, while emphasizing new tumor features and concepts.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Chaelin Lee, Miso Kim, Dong-Wan Kim, Tae Min Kim, Soyeon Kim, Sun-Wha Im, Yoon Kyung Jeon, Bhumsuk Keam, Ja-Lok Ku, Dae Seog Heo
Summary: This study reveals that the T790M mutation in EGFR-KDD confers resistance to 1st and 2nd generation EGFR tyrosine kinase inhibitors (TKIs), but is sensitive to 3rd generation EGFR TKIs. In addition, the study identifies that the C797S mutation in kinase domain 2 of EGFR-KDDT790M mediates a resistance mechanism against 3rd generation EGFR TKIs.
CANCER RESEARCH AND TREATMENT
(2022)
Article
Biochemistry & Molecular Biology
Nguyen Quoc Khanh Le, Quang Hien Kha, Van Hiep Nguyen, Yung-Chieh Chen, Sho-Jen Cheng, Cheng-Yu Chen
Summary: The study introduced a machine learning model for selecting and predicting EGFR and KRAS mutations in NSCLC patients using a minimal number of semantic radiomics features, with the genetic algorithm plus XGBoost classifier showing the best accuracy in detecting these mutations. This noninvasive machine learning-based model demonstrated robust prediction of EGFR and KRAS mutations in patients with NSCLC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Haoyue Hu, Songtao Tan, Meng Xie, Peng Guo, Qiang Yu, Juan Xiao, Kangrui Zhao, Qiong Liao, Yi Wang
Summary: In non-small cell lung cancer, concurrent genetic alterations of epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are rare, but their clinical and pathological characteristics are not well-defined, and the optimal treatment approach remains controversial. This report presents a case of stage IV lung adenocarcinoma with both EGFR and ALK mutations, along with high PD-L1 expression. The patient initially received treatment with EGFR tyrosine kinase inhibitors (TKIs), but the disease progressed, and regression was achieved following a switch to ALK-TKI therapy and local radiotherapy. Our report also provides a comprehensive summary of the clinical and pathological features, as well as treatment strategies, for NSCLC patients with concurrent EGFR mutation and ALK rearrangement.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Eric Rios-Doria, Amir Momeni-Boroujeni, Claire F. Friedman, Pier Selenica, Qin Zhou, Michelle Wu, Antonio Marra, Mario M. Leitao Jr, Alexia Iasonos, Kaled M. Alektiar, Yukio Sonoda, Vicky Makker, Elizabeth Jewell, Ying Liu, Dennis Chi, Dimitry Zamarin, Nadeem R. Abu-Rustum, Carol Aghajanian, Jennifer J. Mueller, Lora H. Ellenson, Britta Weigelt
Summary: By integrating molecular data and immunohistochemistry data, an algorithmic approach was developed to molecularly classify endometrial carcinomas (ECs), resulting in more ECs being classified molecularly compared to using immunohistochemistry. The integrated approach showed prognostic value in both early-stage and advanced-stage EC.
GYNECOLOGIC ONCOLOGY
(2023)
Review
Oncology
Yonghui Wu, Kai Zhang, Jiexia Guan, Weibin Wu, Jian Zhang, Huiguo Chen
Summary: Concurrent mutations of EGFR and PIK3CA in non-small cell lung cancer are rare and may complicate treatment. This case report highlights the challenges in managing such cases, as EGFR and PIK3CA concurrent mutations do not respond well to EGFR-TKI treatment. Combination chemotherapy with a TKI may be more effective in this scenario.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Genetics & Heredity
Rania Abdelmaksoud-Dammak, Nihel Ammous-Boukhris, Amena Saadallah-Kallel, Slim Charfi, Souhir Khemiri, Rim Khemakhem, Nesrin Kallel, Wala Ben Kridis-Rejeb, Tahya Sallemi-Boudawara, Afef Khanfir, Ilhem Yangui, Jamel Daoud, Raja Mokdad-Gargouri
Summary: EGFR mutations were detected in 43% of NSCLC samples, with L861Q mutation being the most common. EGFR mutations were more frequent in female patients, non-smokers, and patients with metastasis. B-raf V600E mutation was identified in some EGFR negative patients.
Review
Oncology
Dan Yan, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Summary: MERTK and AXL are abnormally expressed in the majority of NSCLCs, providing a survival advantage for cells and correlating with metastasis, drug resistance, and disease progression. Host tumor infiltrating cells' TAM receptors also play crucial roles in the immunosuppressive tumor microenvironment. These factors make MERTK and AXL attractive targets for NSCLC treatment.
Article
Oncology
Xiaotong Qiu, Yong Wang, Fen Liu, Lihong Peng, Chen Fang, Xiaoyin Qian, Xinwei Zhang, Qian Wang, Zhehao Xiao, Renfang Chen, Shangkun Yuan, Yong Li
Summary: Studies have shown that non-small cell lung cancer patients with EGFR mutations, but with concurrent PIK3CA mutations, treated with EGFR-TKIs have a shorter time to progression and lower overall survival rates.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Biology
Xiaolong Tang, Lizhi Cheng, Guo Li, Yong-Ming Yan, Fengting Su, Dan-Ling Huang, Shuping Zhang, Zuojun Liu, Minxian Qian, Ji Li, Yong-Xian Cheng, Baohua Liu
Summary: The small molecule compound D6 demonstrates promising efficacy in treating EGFR-TKI resistant NSCLC by targeting the protein-protein interaction between HSP90 and T790M-EGFR, offering a potential alternative strategy to overcome drug resistance.
COMMUNICATIONS BIOLOGY
(2021)
Article
Oncology
Misako Nagasaka, Vijendra Singh, Yasmine Baca, Ammar Sukari, Chul Kim, Hirva Mamdani, Alexander Spira, Dipesh Uprety, Gerold Bepler, Edward S. Kim, Luis E. Raez, Sachin Gopalkrishna Pai, Chukwuemeka Ikpeazu, Matthew Oberley, Rebecca Feldman, Joanne Xiu, W. Michael Korn, Antoinette J. Wozniak, Hossein Borghaei, Stephen Liu
Summary: HER2 alterations can lead to resistance to EGFR tyrosine kinase inhibitors in NSCLC patients. Among the 12,946 samples analyzed, 2.5% had HER2 alterations, with 1.5% of EGFR mutated patients also having concurrent HER2 alterations. Patients with both EGFR mutation and HER2 amplification had longer time on treatment with EGFR TKIs compared to those with EGFR mutation alone. It is important to continue gathering clinical data for further analysis of real-world outcomes.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Jun-Feng Liu, Xu-Sheng Sun, Jin-Huan Yin, Xi-E Xu
Summary: This retrospective study aimed to address the effect of adjuvant chemotherapy before adjuvant EGFR-TKI therapy and the duration of EGFR-TKI therapy on survival outcomes in patients with NSCLC. The results showed that adjuvant EGFR-TKI treatment was effective for patients with stage II-IIIA EGFR-mutation positive NSCLC. Patients with stage I and pathological risk factors were also suitable for receiving adjuvant EGFR-TKI therapy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Cell Biology
Omid Savari, Christopher Febres-Aldana, Jason C. Chang, Rachel E. Fanaroff, Katia Ventura, Francis Bodd, Paul Paik, Murty Vundavalli, Anjali Saqi, Frederic B. Askin, William D. Travis, Natasha Rekhtman
Summary: Lung carcinomas with diffuse TTF1/p40 coexpression represent poorly differentiated NSCLCs with frequent basaloid features and a high rate of FGFR1 amplifications. Molecular testing is important to identify targetable LUAD-type alterations in these tumors.
Article
Oncology
Yuki Katayama, Tadaaki Yamada, Shinsaku Tokuda, Naoko Okura, Naoya Nishioka, Kenji Morimoto, Keiko Tanimura, Yoshie Morimoto, Masahiro Iwasaku, Mano Horinaka, Toshiyuki Sakai, Kenji Kita, Seiji Yano, Koichi Takayama
Summary: EGFR-T790M mutation is a major mechanism of acquired resistance to EGFR-TKIs in lung cancer. The biological characteristics of T790M tumors differ based on treatment regimens with each generation of EGFR-TKI. The maintenance of EGFR dependency after acquiring resistance may depend on the type of EGFR-TKI.
Article
Oncology
Hayato Koba, Hideharu Kimura, Taro Yoneda, Naohiko Ogawa, Kota Tanimura, Yuichi Tambo, Takashi Sone, Kazuyoshi Hosomichi, Atsushi Tajima, Kazuo Kasahara
Summary: The study found that after EGFR-TKI treatment, some patients originally diagnosed with adenocarcinoma underwent histological transformation to small-cell carcinoma, with the detection of common variants. The Notch and ASCL1 signaling pathways may play an important role in the transformation of small-cell carcinoma under TP53 and RB1 inactivation.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Review
Oncology
Benjamin J. Solomon, Cai Cun Zhou, Alexander Drilon, Keunchil Park, Jurgen Wolf, Yasir Elamin, Hannah M. Davis, Victoria Soldatenkova, Andreas Sashegyi, Aimee Bence Lin, Boris K. Lin, Herbert H. Loong, Silvia Novello, Edurne Arriola, Maurice Perol, Koichi Goto, Fernando C. Santini
Summary: Selpercatinib, a highly selective RET inhibitor, demonstrated clinically meaningful antitumor activity with manageable toxicity in RET fusion-positive non-small-cell lung cancer patients. The ongoing Phase III trial, LIBRETTO-431, is evaluating selpercatinib versus chemotherapy in treatment-naive patients with RET fusion-positive nonsquamous non-small-cell lung cancer, with progression-free survival as the primary endpoint.
Article
Oncology
Sai-Hong Ou, Benjamin J. Solomon, Alice T. Shaw, Shirish M. Gadgeel, Benjamin Besse, Ross A. Soo, Antonello Abbattista, Francesca Toffalorio, Robin Wiltshire, Alessandra Bearz
Summary: This study retrospectively analyzed the clinical benefit of continuing Lorlatinib beyond progressive disease in patients with ALK-positive NSCLC. The results showed that continuing LBPD can be a viable treatment strategy for these patients.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
D. S-W. Tan, M. Thomas, D-W. Kim, S. Szpakowski, P. Urban, R. Mehra, L. Q. M. Chow, S. Sharma, B. J. Solomon, E. Felip, D. R. Camidge, J. Vansteenkiste, L. Petruzzelli, S. Pantano, A. T. Shaw
Summary: An exploratory analysis was conducted to understand the genetic determinants of response to ceritinib in ALK+ NSCLC patients. The study revealed the potential role of next-generation sequencing (NGS) in improving our understanding of response and resistance to ceritinib. It also demonstrated the efficacy of ceritinib against almost all ALK resistance mutations found in ALKi-pretreated patients.
Article
Oncology
B. J. Solomon, H. H. Loong, Y. Summers, Z. M. Thomas, P. French, B. K. Lin, A. Sashegyi, J. Wolf, J. C-H Yang, A. Drilon
Summary: This study identified a strong correlation between the treatment effects on ORR and PFS in randomized clinical trials targeting oncogene-addicted tumors, while a weaker correlation was observed between ORR and OS.
Article
Oncology
Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C. Tebbutt, Michael Michael, Emma Link, Stephen Q. Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J. Solomon, Grant A. McArthur, Rodney J. Hicks, Peter Gibbs, Sarah-Jane Dawson, Jayesh Desai
Summary: BRAF V600E mutant metastatic colorectal cancer is a significant clinical problem. Combination therapy with vemurafenib and small-molecule EGFR inhibitors has shown effectiveness in pre-clinical studies, but clinical investigation is lacking.
CLINICAL CANCER RESEARCH
(2023)
Editorial Material
Oncology
Benjamin J. Solomon, Todd M. Bauer, Tony S. K. Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem, Froylan Lopez Lopez, Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip
Editorial Material
Oncology
Trudy C. Wu, Annalise Stube, Carol Felix, Denise Oseguera, Tahmineh Romero, Jonathan Goldman, Edward B. Garon, Jay M. Lee, John Glaspy, Aaron E. Lisberg, Chad G. Rusthoven, D. Ross Camidge, Shankar Siva, Benjamin Solomon, Alan Lee, Stephen E. Tenn, Narek Shaverdian, Michael L. Steinberg, Ann C. Raldow, Percy Lee
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Letter
Oncology
Nicolas Girard, Marina C. Garassino, Benjamin Solomon
JOURNAL OF THORACIC ONCOLOGY
(2023)
Letter
Oncology
Nicolas Girard, Marina C. Garassino, Benjamin Solomon
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Ross A. Soo, Jean-Francois Martini, Anthonie J. van der Wekken, Shunsuke Teraoka, Roberto Ferrara, Alice T. Shaw, Deborah Shepard, Anna Maria Calella, Anna Polli, Francesca Toffalorio, Pascale Tomasini, Chao-Hua Chiu, Dariusz M. Kowalski, Hye Ryun Kim, Benjamin J. Solomon
Summary: In treatment-naive patients with advanced ALK-positive NSCLC, ctDNA can be used as a biomarker to predict the efficacy of lorlatinib treatment.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Medicine, General & Internal
Adrianus Johannes de Langen, Melissa L. Johnson, Julien Mazieres, Anne -Marie C. Dingemans, Giannis Mountzios, Miklos Pless, Jurgen Wolf, Martin Schuler, Herve Lena, Ferdinandos Skoulidis, Yasuto Yoneshima, Sang-We Kim, Helena Linardou, Silvia Novello, Anthonie J. van der Wekken, Yuanbin Chen, Solange Peters, Enriqueta Felip, Benjamin J. Solomon, Suresh S. Ramalingam, Christophe Dooms, Colin R. Lindsay, Carlos Gil Ferreira, Normand Blais, Cynthia C. Obiozor, Yang Wang, Bhakti Mehta, Tracy Varrieur, Gataree Ngarmchamnanrith, Bjorn Stollenwerk, David Waterhouse, Luis Paz-Ares
Summary: This study compared the efficacy and safety of Sotorasib with standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation. The results showed that compared to docetaxel, Sotorasib significantly increased progression-free survival and had a more favorable safety profile.
Review
Oncology
Grace Chazan, Benjamin J. Solomon
Summary: First-line treatment options for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbour anaplastic lymphoma kinase (ALK) gene rearrangements have evolved rapidly. Although newer generation ALK inhibitors have demonstrated superiority to crizotinib, head-to-head clinical trials comparing these inhibitors are lacking. Decisions on optimal first-line treatment must be based on analysis of relevant trials and consideration of various factors.
TRANSLATIONAL LUNG CANCER RESEARCH
(2023)
Review
Medicine, General & Internal
L. B. Cameron, N. Hitchen, E. Chandran, T. Morris, R. Manser, B. J. Solomon, V Jordan
Summary: This study evaluated the safety and efficacy of ALK inhibitors as monotherapy for advanced ALK-rearranged NSCLC. The results showed that ALK inhibitors are effective in improving progression-free survival, overall survival, and overall response rate, with minimal adverse events compared to chemotherapy. Next-generation ALK inhibitors are more effective and safe than first-generation ALK inhibitors. However, further research is needed to compare different next-generation ALK inhibitors.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Article
Endocrinology & Metabolism
Ray Wang, Benjamin Solomon, Stephen J. Luen, Owen W. J. Prall, Christine Khoo, Anthony J. Gill, Jeremy Lewin, Nirupa Sachithanandan
Summary: Adrenocortical carcinoma is a rare disease with significant clinical heterogeneity, presenting a diagnostic challenge to clinicians. Specialist multidisciplinary team input and genomics play vital roles in diagnosis and prognosis of adrenocortical carcinoma.
ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS
(2022)
Meeting Abstract
Oncology
Alessandra Bearz, Jean-Francois Martini, Jacek Jassem, Sang-We Kim, Gee-Chen Chang, Alice Shaw, Deborah Shepard, Elisa Dall'O', Anna Polli, Holger Thurm, Gerard Zalcman, Maria Rosario Garcia Campelo, Konstantin Penkov, Hidetoshi Hayashi, Benjamin J. Solomon